drugset / Trial / NCT00518583
Phase II Study in Patients With Operable Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.
Timeline
- Start
- 2006-10
- Primary completion
- 2009-01
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pegylated liposomal doxorubicin | Unknown | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |